Five Prime Therapeutics, Inc.

Other

Kristen Pierce

Thomas Brennan

Julie Hambleton

Thomas Harding

Namrata Patil

Robert Sikorski

Janine Powers

Majid Ghoddusi

Servando Palencia

Kartik Sundareshwar Krishnan

Provided herein are uses of fibroblast growth factor receptor 2 (FGFR2) inhibitors in cancer treatment, in some cases in combination with immune stimulating agents, such as inhibitors of PD-1 or PD-L1. In some embodiments, FGFR2 inhibitors may comprise FGFR2 antibodies or FGFR2 extracellular domain (ECD) polypeptides, or FGFR2 ECD fusion molecules comprising an FGFR2 ECD and a fusion partner. In some embodiments, PD-1/PD-L1 inhibitors may comprise anti-PD-1 antibodies such as antibodies that bind to PD-1 or to PD-L1 and inhibit interactions between these proteins, as well as PD-1 fusion proteins or polypeptides.

FGFR2 inhibitors alone or in combination with immune stimulating agents in cancer treatment

The present invention provides antibodies that bind FGFR2IIIb, wherein the antibodies are afucosylated. The present invention provides compositions comprising antibodies that bind FGFR2IIIb, wherein at least 95% of the antibodies in the composition are afucosylated. In some embodiments, methods of treating cancer comprising administering afucosylated anti-FGFR2IIIb antibodies are provided.

Afucosylated anti-FGFR2IIIB antibodies

Method of treatment of malignant solid tumors with afucosylated anti-FGFR2IIIb antibodies

Growing community of inventors

Burlingame, CA, United States of America

Kristen Pierce